STRO
Income statement / Annual
Last year (2023), Sutro Biopharma, Inc.'s total revenue was $153.73 M,
an increase of 126.84% from the previous year.
In 2023, Sutro Biopharma, Inc.'s net income was -$106.79 M.
See Sutro Biopharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$153.73 M
|
$67.77 M
|
$61.88 M
|
$42.72 M
|
$42.74 M
|
$38.42 M
|
$51.74 M
|
$59.73 M
|
| Cost of Revenue |
$6.82 M |
$8.29 M |
$9.77 M |
$76.96 M |
$65.61 M |
$54.26 M |
$51.90 M |
$43.55 M |
| Gross Profit |
$146.92 M |
$59.48 M |
$52.11 M |
-$34.24 M |
-$22.88 M |
-$15.84 M |
-$156,000.00 |
$16.18 M |
| Gross Profit Ratio |
0.96 |
0.88 |
0.84 |
-0.8 |
-0.54 |
-0.41 |
-0 |
0.27 |
| Research and Development
Expenses |
$180.43 M
|
$137.17 M
|
$104.40 M
|
$76.96 M
|
$65.61 M
|
$54.26 M
|
$54.64 M
|
$43.55 M
|
| General & Administrative
Expenses |
$62.58 M
|
$59.54 M
|
$56.00 M
|
$36.82 M
|
$32.59 M
|
$21.38 M
|
$16.37 M
|
$14.82 M
|
| Selling & Marketing
Expenses |
-$6.82 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$55.77 M
|
$59.54 M
|
$56.00 M
|
$36.82 M
|
$32.59 M
|
$21.38 M
|
$16.37 M
|
$14.82 M
|
| Other Expenses |
-$180.43 M |
$0.00 |
$0.00 |
$0.00 |
-$4.35 M |
$1.91 M |
-$77,000.00 |
$87,000.00 |
| Operating Expenses |
$236.19 M |
$196.72 M |
$160.40 M |
$113.78 M |
$98.20 M |
$75.64 M |
$71.01 M |
$58.37 M |
| Cost And Expenses |
$243.01 M |
$196.72 M |
$160.40 M |
$113.78 M |
$98.20 M |
$75.64 M |
$71.01 M |
$58.37 M |
| Interest Income |
$14.51 M |
$3.46 M |
$577,000.00 |
$1.51 M |
$4.07 M |
$1.62 M |
$273,000.00 |
$251,000.00 |
| Interest Expense |
$23.75 M |
$3.35 M |
$3.14 M |
$4.08 M |
$4.35 M |
$1.62 M |
$612,000.00 |
$0.00 |
| Depreciation &
Amortization |
$6.82 M
|
$8.29 M
|
$9.77 M
|
$4.30 M
|
$4.78 M
|
$4.54 M
|
$4.99 M
|
$5.66 M
|
| EBITDA |
-$82.46 M
|
-$125.49 M
|
-$93.10 M
|
-$65.25 M
|
-$46.62 M
|
-$29.16 M
|
-$14.09 M
|
$7.36 M
|
| EBITDA Ratio |
-0.54 |
-1.85 |
-1.5 |
-1.53 |
-1.09 |
-0.76 |
-0.27 |
0.12 |
| Operating Income Ratio
|
-0.58
|
-1.9
|
-1.59
|
-1.66
|
-1.3
|
-0.97
|
-0.37
|
0.02
|
| Total Other
Income/Expenses Net |
$677,000.00
|
$12.24 M
|
-$7.01 M
|
$38.93 M
|
-$276,000.00
|
$1.91 M
|
-$77,000.00
|
$87,000.00
|
| Income Before Tax |
-$88.60 M |
-$116.70 M |
-$105.54 M |
-$32.13 M |
-$55.74 M |
-$35.32 M |
-$19.69 M |
$1.70 M |
| Income Before Tax Ratio
|
-0.58
|
-1.72
|
-1.71
|
-0.75
|
-1.3
|
-0.92
|
-0.38
|
0.03
|
| Income Tax Expense |
$18.19 M |
$2.50 M |
$3.14 M |
$4.08 M |
$8.68 M |
$3.53 M |
$535,000.00 |
$87,000.00 |
| Net Income |
-$106.79 M |
-$119.20 M |
-$108.68 M |
-$36.21 M |
-$55.74 M |
-$35.32 M |
-$19.69 M |
$1.70 M |
| Net Income Ratio |
-0.69 |
-1.76 |
-1.76 |
-0.85 |
-1.3 |
-0.92 |
-0.38 |
0.03 |
| EPS |
-1.78 |
-2.35 |
-2.36 |
-1.11 |
-2.43 |
-6.13 |
-2.81 |
0.24 |
| EPS Diluted |
-1.78 |
-2.35 |
-2.36 |
-1.11 |
-2.43 |
-6.13 |
-2.81 |
0.24 |
| Weighted Average Shares
Out |
$60.16 M
|
$50.74 M
|
$46.12 M
|
$32.57 M
|
$22.96 M
|
$5.76 M
|
$7.00 M
|
$7.00 M
|
| Weighted Average Shares
Out Diluted |
$60.16 M
|
$50.74 M
|
$46.12 M
|
$32.57 M
|
$22.96 M
|
$5.76 M
|
$7.00 M
|
$7.00 M
|
| Link |
|
|
|
|
|
|
|
|
